Copyright Reports & Markets. All rights reserved.

Global Antivenom Market Insights and Forecast to 2027

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Antivenom Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Antivenom Market Size Growth Rate by Type
    • 1.4.2 Polyvalent antivenom
    • 1.4.3 Monovalent antivenom
  • 1.3 Market by Application
    • 1.3.1 Global Antivenom Market Size Growth Rate by Application
    • 1.3.2 Non-profit Institutions
    • 1.3.3 Hospitals and Clinic
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Antivenom Sales Estimates and Forecasts 2016-2027
  • 2.2 Global Antivenom Revenue Estimates and Forecasts 2016-2027
  • 2.3 Global Antivenom Revenue by Region: 2016 VS 2021 VS 2027
  • 2.4 Global Top Antivenom Regions by Sales
    • 2.4.1 Global Top Antivenom Regions by Sales (2016-2021)
    • 2.4.2 Global Top Antivenom Regions by Sales (2022-2027)
  • 2.5 Global Top Antivenom Regions by Revenue
    • 2.5.1 Global Top Antivenom Regions by Revenue (2016-2021)
    • 2.5.2 Global Top Antivenom Regions by Revenue (2022-2027)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Antivenom Sales by Manufacturers
    • 3.1.1 Global Top Antivenom Manufacturers by Sales (2016-2021)
    • 3.1.2 Global Top Antivenom Manufacturers Market Share by Sales (2016-2021)
    • 3.1.3 Global Top 10 and Top 5 Companies by Antivenom Sales in 2020
  • 3.2 Global Antivenom Revenue by Manufacturers
    • 3.2.1 Global Top Antivenom Manufacturers by Revenue (2016-2021)
    • 3.2.2 Global Top Antivenom Manufacturers Market Share by Revenue (2016-2021)
    • 3.2.3 Global Top 10 and Top 5 Companies by Antivenom Revenue in 2020
  • 3.3 Global Antivenom Sales Price by Manufacturers
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Antivenom Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Antivenom Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Antivenom Sales by Type
    • 4.1.1 Global Antivenom Historical Sales by Type (2016-2021)
    • 4.1.2 Global Antivenom Forecasted Sales by Type (2022-2027)
    • 4.1.3 Global Antivenom Sales Market Share by Type (2016-2027)
  • 4.2 Global Antivenom Revenue by Type
    • 4.2.1 Global Antivenom Historical Revenue by Type (2016-2021)
    • 4.2.2 Global Antivenom Forecasted Revenue by Type (2022-2027)
    • 4.2.3 Global Antivenom Revenue Market Share by Type (2016-2027)
  • 4.3 Global Antivenom Price by Type
    • 4.3.1 Global Antivenom Price by Type (2016-2021)
    • 4.3.2 Global Antivenom Price Forecast by Type (2022-2027)

5 Market Size by Application

  • 5.1 Global Antivenom Sales by Application
    • 5.1.1 Global Antivenom Historical Sales by Application (2016-2021)
    • 5.1.2 Global Antivenom Forecasted Sales by Application (2022-2027)
    • 5.1.3 Global Antivenom Sales Market Share by Application (2016-2027)
  • 5.2 Global Antivenom Revenue by Application
    • 5.2.1 Global Antivenom Historical Revenue by Application (2016-2021)
    • 5.2.2 Global Antivenom Forecasted Revenue by Application (2022-2027)
    • 5.2.3 Global Antivenom Revenue Market Share by Application (2016-2027)
  • 5.3 Global Antivenom Price by Application
    • 5.3.1 Global Antivenom Price by Application (2016-2021)
    • 5.3.2 Global Antivenom Price Forecast by Application (2022-2027)

6 North America

  • 6.1 North America Antivenom Market Size by Type
    • 6.1.1 North America Antivenom Sales by Type (2016-2027)
    • 6.1.2 North America Antivenom Revenue by Type (2016-2027)
  • 6.2 North America Antivenom Market Size by Application
    • 6.2.1 North America Antivenom Sales by Application (2016-2027)
    • 6.2.2 North America Antivenom Revenue by Application (2016-2027)
  • 6.3 North America Antivenom Market Size by Country
    • 6.3.1 North America Antivenom Sales by Country (2016-2027)
    • 6.3.2 North America Antivenom Revenue by Country (2016-2027)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Antivenom Market Size by Type
    • 7.1.1 Europe Antivenom Sales by Type (2017-2027)
    • 7.1.2 Europe Antivenom Revenue by Type (2017-2027)
  • 7.2 Europe Antivenom Market Size by Application
    • 7.2.1 Europe Antivenom Sales by Application (2017-2027)
    • 7.2.2 Europe Antivenom Revenue by Application (2017-2027)
  • 7.3 Europe Antivenom Market Size by Country
    • 7.3.1 Europe Antivenom Sales by Country (2017-2027)
    • 7.3.2 Europe Antivenom Revenue by Country (2017-2027)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Antivenom Market Size by Type
    • 8.1.1 Asia Pacific Antivenom Sales by Type (2018-2027)
    • 8.1.2 Asia Pacific Antivenom Revenue by Type (2018-2027)
  • 8.2 Asia Pacific Antivenom Market Size by Application
    • 8.2.1 Asia Pacific Antivenom Sales by Application (2018-2027)
    • 8.2.2 Asia Pacific Antivenom Revenue by Application (2018-2027)
  • 8.3 Asia Pacific Antivenom Market Size by Region
    • 8.3.1 Asia Pacific Antivenom Sales by Region (2018-2027)
    • 8.3.2 Asia Pacific Antivenom Revenue by Region (2018-2027)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Antivenom Market Size by Type
    • 9.1.1 Latin America Antivenom Sales by Type (2019-2027)
    • 9.1.2 Latin America Antivenom Revenue by Type (2019-2027)
  • 9.2 Latin America Antivenom Market Size by Application
    • 9.2.1 Latin America Antivenom Sales by Application (2019-2027)
    • 9.2.2 Latin America Antivenom Revenue by Application (2019-2027)
  • 9.3 Latin America Antivenom Market Size by Country
    • 9.3.1 Latin America Antivenom Sales by Country (2019-2027)
    • 9.3.2 Latin America Antivenom Revenue by Country (2019-2027)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

6 Middle East and Africa

  • 6.1 Middle East and Africa Antivenom Market Size by Type
    • 6.1.1 Middle East and Africa Antivenom Sales by Type (2016-2027)
    • 6.1.2 Middle East and Africa Antivenom Revenue by Type (2016-2027)
  • 6.2 Middle East and Africa Antivenom Market Size by Application
    • 6.2.1 Middle East and Africa Antivenom Sales by Application (2016-2027)
    • 6.2.2 Middle East and Africa Antivenom Revenue by Application (2016-2027)
  • 6.3 Middle East and Africa Antivenom Market Size by Country
    • 6.3.1 Middle East and Africa Antivenom Sales by Country (2016-2027)
    • 6.3.2 Middle East and Africa Antivenom Revenue by Country (2016-2027)
    • 6.3.3 Turkey
    • 6.3.4 Saudi Arabia
    • 6.3.5 U.A.E

11 Company Profiles

  • 11.1 CSL
    • 11.1.1 CSL Corporation Information
    • 11.1.2 CSL Overview
    • 11.1.3 CSL Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 CSL Antivenom Product Description
    • 11.1.5 CSL Related Developments
  • 11.2 Merck
    • 11.2.1 Merck Corporation Information
    • 11.2.2 Merck Overview
    • 11.2.3 Merck Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.2.4 Merck Antivenom Product Description
    • 11.2.5 Merck Related Developments
  • 11.3 BTG
    • 11.3.1 BTG Corporation Information
    • 11.3.2 BTG Overview
    • 11.3.3 BTG Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.3.4 BTG Antivenom Product Description
    • 11.3.5 BTG Related Developments
  • 11.4 Pfizer
    • 11.4.1 Pfizer Corporation Information
    • 11.4.2 Pfizer Overview
    • 11.4.3 Pfizer Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.4.4 Pfizer Antivenom Product Description
    • 11.4.5 Pfizer Related Developments
  • 11.5 Haffkine Bio-Pharmaceutical
    • 11.5.1 Haffkine Bio-Pharmaceutical Corporation Information
    • 11.5.2 Haffkine Bio-Pharmaceutical Overview
    • 11.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.5.4 Haffkine Bio-Pharmaceutical Antivenom Product Description
    • 11.5.5 Haffkine Bio-Pharmaceutical Related Developments
  • 11.6 Rare Disease Therapeutics
    • 11.6.1 Rare Disease Therapeutics Corporation Information
    • 11.6.2 Rare Disease Therapeutics Overview
    • 11.6.3 Rare Disease Therapeutics Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.6.4 Rare Disease Therapeutics Antivenom Product Description
    • 11.6.5 Rare Disease Therapeutics Related Developments
  • 11.7 Flynn Pharma
    • 11.7.1 Flynn Pharma Corporation Information
    • 11.7.2 Flynn Pharma Overview
    • 11.7.3 Flynn Pharma Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.7.4 Flynn Pharma Antivenom Product Description
    • 11.7.5 Flynn Pharma Related Developments
  • 11.8 Vins Bioproducts
    • 11.8.1 Vins Bioproducts Corporation Information
    • 11.8.2 Vins Bioproducts Overview
    • 11.8.3 Vins Bioproducts Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.8.4 Vins Bioproducts Antivenom Product Description
    • 11.8.5 Vins Bioproducts Related Developments
  • 11.9 Bharat Serums and Vaccines
    • 11.9.1 Bharat Serums and Vaccines Corporation Information
    • 11.9.2 Bharat Serums and Vaccines Overview
    • 11.9.3 Bharat Serums and Vaccines Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.9.4 Bharat Serums and Vaccines Antivenom Product Description
    • 11.9.5 Bharat Serums and Vaccines Related Developments
  • 11.10 Serum Biotech
    • 11.10.1 Serum Biotech Corporation Information
    • 11.10.2 Serum Biotech Overview
    • 11.10.3 Serum Biotech Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.10.4 Serum Biotech Antivenom Product Description
    • 11.10.5 Serum Biotech Related Developments
  • 11.1 CSL
    • 11.1.1 CSL Corporation Information
    • 11.1.2 CSL Overview
    • 11.1.3 CSL Antivenom Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 CSL Antivenom Product Description
    • 11.1.5 CSL Related Developments

12 Value Chain and Sales Channels Analysis

  • 12.1 Antivenom Value Chain Analysis
  • 12.2 Antivenom Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Antivenom Production Mode & Process
  • 12.4 Antivenom Sales and Marketing
    • 12.4.1 Antivenom Sales Channels
    • 12.4.2 Antivenom Distributors
  • 12.5 Antivenom Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Antivenom Industry Trends
  • 13.2 Antivenom Market Drivers
  • 13.3 Antivenom Market Challenges
  • 13.4 Antivenom Market Restraints

14 Key Findings in The Global Antivenom Study

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details

    Antivenom market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antivenom market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

    Segment by Type
    Polyvalent antivenom
    Monovalent antivenom

    Segment by Application
    Non-profit Institutions
    Hospitals and Clinic

    By Company
    CSL
    Merck
    BTG
    Pfizer
    Haffkine Bio-Pharmaceutical
    Rare Disease Therapeutics
    Flynn Pharma
    Vins Bioproducts
    Bharat Serums and Vaccines
    Serum Biotech
    MicroPharm

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia

    Buy now